Patents by Inventor Chandregowda Venkateshappa
Chandregowda Venkateshappa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250136553Abstract: The present disclosure describes acylsulfonamide compounds of Formula (J), and pharmaceutically acceptable salts, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.Type: ApplicationFiled: December 23, 2024Publication date: May 1, 2025Inventors: Brian R. Hearn, David C. Myles, Reena Chawla, David Yeghikyan, Chandregowda Venkateshappa, Susanta Samajdar, Kalisankar Bera, Suraj Tatyasaheb Gore, Raymond A. Ng
-
Publication number: 20250059204Abstract: The present invention provides fused benzoisoxazolyl compounds represented by compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of the diseases or disorders mediated by KAT6A in a subject. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.Type: ApplicationFiled: December 12, 2022Publication date: February 20, 2025Inventors: Chandregowda Venkateshappa, Kalisankar Bera, Chandrasekhar Abbineni, Susanta Samajdar, David C. Myles, Brian R. Hearn
-
Publication number: 20240254139Abstract: The present invention provides fused isoxazolyl compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases or disorders dependent upon KAT6A in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compound represented by formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.Type: ApplicationFiled: May 21, 2022Publication date: August 1, 2024Inventors: Chandregowda Venkateshappa, Chandrasekhar Abbineni, Susanta Samajdar, Kalisankar Bera
-
Publication number: 20230183239Abstract: Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.Type: ApplicationFiled: March 23, 2022Publication date: June 15, 2023Inventors: William Michael GALLATIN, Joshua ODINGO, Gregory N. DIETSCH, Vincent FLORIO, Chandregowda VENKATESHAPPA, Athisayamani Jeyaraj DURAISWAMY
-
Patent number: 11629135Abstract: The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation.Type: GrantFiled: November 6, 2018Date of Patent: April 18, 2023Assignee: JUBILANT PRODELL LLCInventors: Chandregowda Venkateshappa, Athisayamani Jeyaraj Duraiswamy, Rama Kishore V P Putta, Sridharan Rajagopal
-
Publication number: 20230027075Abstract: The present invention relates to bispecific compound of formula (I) as dual inhibitors of CD73 and adenosine receptors. The present invention also relates to pharmaceutical compositions comprising said compounds or a pharmaceutically acceptable salt or a stereoisomer or a prodrug thereof and use of such compounds in the treatment of diseases mediated by CD73 and/or adenosine receptors, particularly A2aR or A2bR.Type: ApplicationFiled: November 26, 2020Publication date: January 26, 2023Inventors: Susanta SAMAJDAR, Dinesh CHIKKANNA, Sunil Kumar PANIGRAHI, Chandregowda VENKATESHAPPA, Garima PRIYADARSHANI
-
Publication number: 20230027026Abstract: The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.Type: ApplicationFiled: September 26, 2020Publication date: January 26, 2023Inventors: Chandregowda Venkateshappa, Dhanalakshmi Sivanandhan, Sridharan Rajagopal, Bruce Roth, Anjali Pandey, Tracy Saxton, Gurulingappa Hallur, Naveena Madhyastha, Naveen Sadhu M
-
Patent number: 11529341Abstract: The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.Type: GrantFiled: March 13, 2019Date of Patent: December 20, 2022Inventors: Chandregowda Venkateshappa, Jeyaraj D A, Muralidhar Pendyala, Dhanalakshmi Sivanandhan, Sridharan Rajagopal
-
Publication number: 20220098214Abstract: The present invention provides compounds and methods for treating MKP5 modulated disease. In certain embodiments, the MKP5 modulated disease is a fibrotic disease.Type: ApplicationFiled: January 30, 2020Publication date: March 31, 2022Inventors: Anton BENNETT, Gurulingappa HALLUR, Chandregowda VENKATESHAPPA, Athisayamani Jeyaraj DURAISWAMY, Rama Kishore V.P. PUTTA
-
Publication number: 20210179580Abstract: The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation.Type: ApplicationFiled: November 6, 2018Publication date: June 17, 2021Inventors: Chandregowda VENKATESHAPPA, Athisayamani Jeyaraj DURAISWAMY, Rama Kishore V P PUTTA, Sridharan RAJAGOPAL
-
Publication number: 20210015810Abstract: The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.Type: ApplicationFiled: March 13, 2019Publication date: January 21, 2021Inventors: Chandregowda VENKATESHAPPA, Jeyaraj DA, Muralidhar PENDYALA, Dhanalakshmi SIVANANDHAN, Sridharan RAJAGOPAL
-
Publication number: 20190241573Abstract: The invention is directed to substituted isoquinoline derivatives and uses thereof. Specifically, the invention is directed to compounds according to Formula I and the use of compounds of Formula (I) in treating disease states: wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined herein.Type: ApplicationFiled: July 18, 2017Publication date: August 8, 2019Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Jeffrey Michael AXTEN, Raghava Reddy KETHIRI, Rajendra KRISTAM, Chandregowda VENKATESHAPPA
-
Patent number: 10273224Abstract: The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.Type: GrantFiled: July 10, 2014Date of Patent: April 30, 2019Assignee: Jubilant Biosys LimitedInventors: Chandregowda Venkateshappa, Dhanalakshmi Sivanandhan, Rajagopal Bakthavatchalam, Raghava Reddy Kethiri, Vellarkad Narayana Viswanadhan, Sanjeev Giri
-
Publication number: 20180237441Abstract: The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein.Type: ApplicationFiled: September 15, 2016Publication date: August 23, 2018Inventors: Jeffrey Michael AXTEN, Alain Claude-Marie DAUGAN, Nicolas Eric FAUCHER, Raghava Reddy KETHIRI, Rajendra KRISTAM, Chandregowda VENKATESHAPPA
-
Publication number: 20180230098Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: April 13, 2018Publication date: August 16, 2018Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Patent number: 9969687Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: GrantFiled: December 22, 2014Date of Patent: May 15, 2018Assignee: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Publication number: 20170073339Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.Type: ApplicationFiled: November 23, 2016Publication date: March 16, 2017Inventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
-
Publication number: 20170002011Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: December 22, 2014Publication date: January 5, 2017Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Publication number: 20170001959Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: December 22, 2014Publication date: January 5, 2017Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Patent number: 9533981Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.Type: GrantFiled: November 13, 2013Date of Patent: January 3, 2017Assignee: Asana BioSciences, LLCInventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj